NTRK1 and non-small cell lung carcinoma: Appearance of EGFR tyrosine kinase receptor inhibitors (TKI)had brought a revolutionary change in non-small cell lung cancer(NSCLC), such as gefitinib, erlotinib, afatinib and AZD9291, especially those with adenocarcinomas [3].